Since then, the MHRA has considered the success of dc-vax for other types of cancer being treated under compassionate care and started working with NWBO to expand the scope beyond just for glioblastoma.
"That is not how the process works. Additional indications are added via Variations (or sBLA/sNDA for the FDA)."
yes, but variations are submitted while under MHRA review.
also, nice to 2 see 2 fudsters going against my analysis, must mean I'm close
Market Data 
Markets 
AI
